CALC
What one share of CalciMedica holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Our product candidates target calcium release-activated calcium (“CRAC”) channels and, if approved, would represent a new class of therapeutics.
CalciMedica’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.33 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.20 |
| Cash and investments | $0.61 |
| Book value | $0.18 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$111.16 | $0.05 | −$143.00 | — | −$847.19 |
| 2023 | — | −$7.66 | $0.02 | −$5.75 | — | $1.42 |
| 2024 | — | −$1.22 | $0.00 | −$1.88 | — | $1.07 |
| 2025 | — | −$1.97 | $0.00 | −$1.41 | — | −$0.43 |